UBC successfully managed a large global phase III clinical trial in patients with mCRC refractory to standard chemotherapies. The target was to randomize 800 patients in an 18-month period. The trial ran in 113 sites, across 13 countries. This was a full service contract, with UBC being responsible for all activities related to study execution and analysis. Read how UBC successfully completed patient enrollment 3 months ahead of schedule and database lock 3.5 months ahead of schedule.